Navigation Links
Cardium Reports on Second Quarter 2008 Highlights and Financial Results
Date:8/11/2008

involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release pu
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
4. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
7. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
10. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... April 20, 2015 Research published today in ... Sciences (PNAS) demonstrates that technology invented by ... Casey Eye Institute can improve the clinical ... coherence tomography (OCT) angiography could largely replace current ... OHSU researchers found that OCT angiography ...
(Date:4/20/2015)... CAMBRIDGE, Mass. , April 20, 2015 /PRNewswire/ ... updated and final clinical results for the Phase ... doxorubicin, in HER2-positive metastatic breast cancer.  The results ... a clinical trials plenary oral session at the ... Meeting in Philadelphia, PA. ...
(Date:4/20/2015)... , April 20, 2015 This report analyzes the ... US$ Million by the following Product Segments: Sphygmomanometers (Aneroid Sphygmomanometers, ... Pressure Transducers. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts are provided ...
Breaking Medicine Technology:Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5World Blood Pressure Monitoring and Measurement Instruments Industry 2World Blood Pressure Monitoring and Measurement Instruments Industry 3World Blood Pressure Monitoring and Measurement Instruments Industry 4World Blood Pressure Monitoring and Measurement Instruments Industry 5World Blood Pressure Monitoring and Measurement Instruments Industry 6World Blood Pressure Monitoring and Measurement Instruments Industry 7World Blood Pressure Monitoring and Measurement Instruments Industry 8World Blood Pressure Monitoring and Measurement Instruments Industry 9World Blood Pressure Monitoring and Measurement Instruments Industry 10World Blood Pressure Monitoring and Measurement Instruments Industry 11World Blood Pressure Monitoring and Measurement Instruments Industry 12World Blood Pressure Monitoring and Measurement Instruments Industry 13World Blood Pressure Monitoring and Measurement Instruments Industry 14World Blood Pressure Monitoring and Measurement Instruments Industry 15World Blood Pressure Monitoring and Measurement Instruments Industry 16World Blood Pressure Monitoring and Measurement Instruments Industry 17World Blood Pressure Monitoring and Measurement Instruments Industry 18World Blood Pressure Monitoring and Measurement Instruments Industry 19World Blood Pressure Monitoring and Measurement Instruments Industry 20World Blood Pressure Monitoring and Measurement Instruments Industry 21World Blood Pressure Monitoring and Measurement Instruments Industry 22World Blood Pressure Monitoring and Measurement Instruments Industry 23World Blood Pressure Monitoring and Measurement Instruments Industry 24World Blood Pressure Monitoring and Measurement Instruments Industry 25World Blood Pressure Monitoring and Measurement Instruments Industry 26World Blood Pressure Monitoring and Measurement Instruments Industry 27World Blood Pressure Monitoring and Measurement Instruments Industry 28
... SAN MATEO, Calif., July 1, 2011 Sonitus Medical, Inc., ... and removable hearing device to transmit sound via the teeth, ... for its SoundBite Hearing System. The FDA 510(k) clearance for ... device and marks another significant milestone for the company. ...
... Alere Inc. (NYSE: ALR ) ("Alere") ... facilities totaling $2.1 billion.  Jefferies Finance LLC, GE Capital ... acted as joint lead arrangers for the credit facilities, ... agent for the lenders under the credit facilities. ...
Cached Medicine Technology:Sonitus Medical Receives Second FDA Clearance for SoundBite™ Hearing System 2Alere Inc. Announces $2.1 Billion Credit Facilities 2
(Date:4/20/2015)... Global Lyme Alliance (GLA) announced today that its ... Hyatt Regency Greenwich, raised over $850,000 to fund research ... tick-borne diseases. , “We are extremely grateful to ... this year’s Gala such a success,” said Robert Kobre, ... initiatives to ultimately find a cure for Lyme ...
(Date:4/20/2015)... 20, 2015 Mauritius is a seemingly ... Located some 2,000 km (1,243 miles) off the southeastern ... cultural and religious melting pot where everyone lives together ... darker reality. Mauritius is riddled with drug abuse. In ... of opiate consumption of any nation in eastern Africa. ...
(Date:4/20/2015)... IL (PRWEB) April 20, 2015 ... Inc., has secured nationally-renowned Gastroenterologist Lawrence Kosinski, MD, ... , Dr. Kosinski brings a unique combination ... vision to the Mutare Health team ... improved communication, collaboration, and quality of care in ...
(Date:4/20/2015)... Novatus, a leading provider of ... service level to the growing European market by ... Paris. After a rigorous review process Novatus ... resilience, security and operational expertise, and extensive connectivity. ... as we expand our footprint and capabilities to ...
(Date:4/20/2015)... New York, New York (PRWEB) April 20, 2015 ... the trade association representing the U.S. health insurance ... as a result of the recent controversy involving ... In a letter to U.S. Senator Robert Casey ... the safety concerns surrounding uterine morcellation point to ...
Breaking Medicine News(10 mins):Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 2Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 3Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Novatus Expands into European Data Centers 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4
... delivering,albuterol, a fast-acting bronchial dilator, currently use propellants such ... December 31st,2009, or replacement HFA,s. Both propellants are also ... near-supersonic speeds. , ... of air by ejecting,the medication from a microfluidic pump ...
... without health insurance for all or some of 2007, according ... for Health Policy Research. , Drawing ... (CHIS), the policy brief,s authors found that 6.4 million Californians ... 2007, the most recent year for which comprehensive statewide data ...
... profiling, In-Stream profiling, data quality and MDM discovery solutions announces today ... (MMA), joining Microsoft Corp. and other key industry partners working together ... the Microsoft® platform. , ... Chicago, IL (PRWEB) December ...
... brand jeans appeal to people who seek intimacy in ... According to a new study in the Journal ... their brand choices. , In psychology, different relationship ... Vanitha Swaminathan, Karen M. Stilley (University of Pittsburgh), and ...
... particular gene could put brakes on killer disease, scientists ... produced by a particular gene may provide a new ... , Experiments at the Mayo Clinic College of Medicine ... down a key pathway in another gene that, in ...
... Mediocre or Near-Failing Grades , , ... care system mean more people than ever before are relying on ... mediocre C- grade for it support of emergency patients, according to ... Dr. Nicholas Jouriles, president of the American College of Emergency Physicians ...
Cached Medicine News:Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 3Health News:Nearly 6.4 million Californians lack health insurance, report shows 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 3Health News:Filling in the gaps: Personality types lead people to choose certain brands 2Health News:Pancreatic Cancer May Have a New Foe 2Health News:VIDEO from Medialink and ACEP: Nation's Failure to Support Emergency Patients Graded C- in National Report Card 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: